Rousselot Receives U.S. Patent for Nextida GC Collagen Peptide Blood Glucose Regulation

Rousselot, a health brand owned by Darling Ingredients, has received a U.S. patent for its collagen peptide composition, Nextida® GC. The patent recognizes the product’s role in supporting blood glucose regulation, marking the first time a collagen peptide composition has received such a designation for this specific health application.

The U.S. Patent and Trademark Office granted the patent following research into the physiological effects of the specific peptide formulation. The company developed Nextida® GC to assist in managing blood glucose levels, a process that involves the interaction of collagen peptides with metabolic functions. This patent provides legal protection for the composition and its intended use in the health and nutrition market. Darling Ingredients confirmed the patent issuance on June 3, 2026, as part of its ongoing development of collagen-based health solutions.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: June 3, 2026

Author

GOAI